

# A Letter on the Urgent Need for Targeted Prostate Cancer Screening

The Rt Hon Wes Streeting MP  
Secretary of State for Health and Social Care

24 November 2025

Dear Secretary of State,

We write united by a belief that no man should die because of his postcode, ethnicity, or GP access.

Prostate cancer is now the most common cancer in UK men, with over 63,000 diagnoses and 12,000 deaths annually.<sup>i</sup> This week, the UK National Screening Committee (UK NSC) meets to decide on prostate cancer screening. This is a defining moment for men's health. The Government must be ready to act so that those at highest risk – men aged 45–69 who are Black, have a family history of prostate, breast or ovarian cancer, or carry BRCA1/BRCA2 variants, all of whom face at least twice the average risk of developing prostate cancer – are no longer left behind.<sup>ii</sup>

## 1) A growing inequity

The latest National Prostate Cancer Audit (2025) shows inequalities are deepening. Men in deprived areas are more likely to present with advanced disease and more likely to die.<sup>iii</sup> Our current opportunistic PSA testing system is unstructured, inefficient and unfair – a postcode lottery where some men succeed because they know to ask or can pay privately, while others are turned away despite repeated requests.

Yet the data hide what cannot be modelled: eroded trust among communities who feel abandoned. Black men, already at higher risk, often believe the system fails them. Families bear devastating emotional and financial burdens from late-stage disease – costs absent from formal modelling but among the most compelling reasons to act.

## 2) The evidence is now clear

The evidence shows screening saves lives. The 23-year follow-up of the European Randomised Study of Screening for Prostate Cancer demonstrated a 13% mortality reduction – comparable to breast and bowel screening, with the numbers needed to screen and treat to prevent a death in line with those for existing programmes.<sup>iv v</sup>

Modern diagnostic pathways have transformed safety. Prostate Cancer UK's 2024 analysis found harms reduced by 79% thanks to MRI and improved biopsy techniques.<sup>vi</sup> The Göteborg-2 trial confirmed pre-biopsy MRI halves overdiagnosis.<sup>vii</sup>

Today, the pathway is entirely different to when the UK NSC last evaluated screening: men have an MRI before any biopsy is considered; biopsies are carried out using safer transperineal methods; and low-grade cancers are far less likely to be detected – and, when they are, they are managed with active surveillance rather than treatment. Harms that once justified inaction have largely been engineered out.

These advances mean we now have the tools to deliver screening safely and effectively, yet the system is frozen waiting for next-generation trial data. Comments in *The Times* (3 October) suggest results from the upcoming TRANSFORM trial may take over a decade.<sup>viii</sup> Waiting would entrench inequality and allow preventable deaths. Evidence is strong enough to act now. Perfection must not be the enemy of progress.

### 3) Practical, affordable and efficient

Targeted screening is practical and affordable. Prostate Cancer Research's 2025 report, *Prostate Cancer Screening: The Impact on the NHS*, with modelling by Carnall Farrar, shows additional annual costs would be around £25m – just 0.01% of the NHS budget – with modest workforce uplift and costs per screen comparable to existing programmes.<sup>ix</sup> Recent data also show a simplified MRI, taking 10 minutes, is as effective as current scans, opening the path to increased capacity within existing resources.<sup>x</sup>

The socio-economic benefits are substantial. Deloitte UK modelling found a five-year targeted programme would deliver a net benefit of £54m through earlier diagnosis, reduced treatment costs, and quality-of-life gains.<sup>xi</sup> Late-stage treatment averages £127,000 per patient vs. £13,000 for early-stage.<sup>xii</sup> Every delay costs lives and money.

Public support is overwhelmingly behind action: a nationally representative Healthwatch England poll of 3,575 men found 79% would attend screening if invited.<sup>xiii</sup> Tens of thousands have called on Parliament to act. We have a duty to listen, and to act.

### 4) Learning from the world

The UK can lead but risks falling behind. Sweden's Organised Prostate Testing (OPT) programme shows that structured, equitable testing is achievable even without a formal programme, laying the groundwork for a future national rollout.<sup>xiv</sup> Across Europe, the EU is implementing its prostate cancer screening recommendation, and Australia is preparing to endorse risk-adapted testing for high-risk men.<sup>xv xvi</sup>

Introducing targeted screening would be a legacy-defining advance for men's health, aligned with the ambitions of the Men's Health Strategy and the National Cancer Plan.

Yours sincerely,

Mr Calvin Bailey MBE MP  
Mr Shockat Adam MP  
Mr Jas Athwal MP  
Ms Alex Baker MP  
Mr Danny Beales MP  
Mr Clive Betts MP  
Mr Chris Bloore MP  
Ms Charlotte Cane MP  
Mr Danny Chambers MP  
The Rt Hon Sir James Cleverly TD VR MP  
Mr Adam Dance MP  
Mr Paul Davies MP  
Mr Lee Dillon MP  
Mr Neil Duncan-Jordan MP  
Mr Colum Eastwood MP  
Mr Clive Efford MP  
Mr Paul Foster MP  
Ms Rachel Gilmour MP  
Mr Andrew Gwynne MP  
Ms Monica Harding MP  
Ms Alison Hume MP  
Mr Terry Jermy MP  
Mr Chris Kane MP  
Mr Ben Lake MP  
Ms Helen Maguire MP  
Mr Charlie Maynard MP  
The Rt Hon John McDonnell MP  
Mr John Milne MP  
Ms Katrina Murray MP  
Ms Sarah Olney MP  
Mr Richard Quigley MP

Ms Helen Morgan MP  
Mr Sadik Al-Hassan MP  
Mr Josh Babarinde OBE MP  
Mr Alex Ballinger MP  
Ms Alison Bennett MP  
Mr Saqib Bhatti MP  
Mr Jonathan Brash MP  
Mr David Chadwick MP  
Mr Bambos Charalambous MP  
Mr Ben Coleman MP  
Mr Steve Darling MP  
Ms Carla Denyer MP  
Dame Caroline Dinenage MP DBE  
Ms Sarah Dyke MP  
Ms SORCHA Eastwood MP  
Ms Linsey Farnsworth MP  
Ms Mary Foy MP  
Mr Olly Glover MP  
Ms Sarah Hall MP  
Mr Chris Hinchliff MP  
Ms Christine Jardine MP  
Mr Clive Jones MP  
Mr Ayoub Khan MP  
Mr Clive Lewis MP  
Ms Rachael Maskell MP  
Mr Douglas McAllister MP  
Mr Kevin McKenna MP  
Mr Iqbal Mohamed MP  
Ms Samantha Niblett MP  
Mr Michael Payne MP  
Ms Yasmin Qureshi MP

The Rt Hon Rishi Sunak MP  
Dr Scott Arthur MP  
Mr Gareth Bacon MP  
Ms Paula Barker MP  
Ms Siân Berry MP  
Mr Matt Bishop MP  
Mr Markus Campbell-Savours MP  
Ms Wendy Chamberlain MP  
Dr Ellie Chowns MP  
Mr John Cooper MP  
Ms Emily Darlington MP  
Mr Jim Dickson MP  
Mr Graeme Downie MP  
Mr Alex Easton MP  
Ms Cat Eccles MP  
Mr Josh Fenton-Glynn MP  
Mr Daniel Francis MP  
Mr Tom Gordon MP  
Ms Paulette Hamilton MP  
Ms Wera Hobhouse MP  
Ms Liz Jarvis MP  
Ms Lillian Jones MP  
Ms Jayne Kirkham MP  
Mr Seamus Logan MP  
Dr Brian Mathew MP  
Mr Andy McDonald MP  
Mr Calum Miller MP  
Mr Edward Morello MP  
Mr Ben Obese-Jecty MP  
Ms Manuela Perteghella MP  
Mr Andrew Ranger MP

Ms Bell Ribeiro-Addy MP	Mr Dave Robertson MP	Mr Andrew Rosindell MP
Ms Sarah Russell MP	Dr Roz Savage MP	Mr Jim Shannon MP
Ms Vikki Slade MP	Ms Cat Smith MP	Mr Greg Smith MP
The Rt Hon Sir Julian Smith, KCB, CBE MP	Mr Andrew Snowden MP	Mr Ian Sollom MP
Mr Gregory Stafford MP	Mr Will Stone MP	Ms Kirsteen Sullivan MP
Mr Luke Taylor MP	Mr Bradley Thomas MP	Mr Cameron Thomas MP
Mr Derek Twigg MP	Mr Martin Vickers MP	Mr Chris Webb MP
Mr Michael Wheeler MP	Mr John Whitby MP	Ms Jo White MP
The Rt Hon Sir Gavin Williamson CBE MP	Ms Munira Wilson MP	Mr Sean Woodcock MP
Mr Martin Wrigley MP	Mr Steve Yemm MP	Ms Claire Young MP
Mr Josh Dean MP	Mr Mike Wood MP	

---

<sup>i</sup> [prostatecanceruk.org/for-health-professionals/data-and-evidence](https://prostatecanceruk.org/for-health-professionals/data-and-evidence)

<sup>ii</sup> James ND, Tannock I, N'Dow J et al. The Lancet Commission on prostate cancer: planning for the surge in cases. *Lancet*. 2024 Apr 27;403(10437):1683-1722. doi: 10.1016/S0140-6736(24)00651-2. Epub 2024 Apr 4. Erratum in: *Lancet*. 2024 Apr 27;403(10437):1634. doi: [10.1016/S0140-6736\(24\)00748-7](https://doi.org/10.1016/S0140-6736(24)00748-7)

<sup>iii</sup> National Prostate Cancer Audit (NPCA) State of the Nation Report 2025. London: National Cancer Audit Collaborating Centre, Royal College of Surgeons of England, 2025. [natcan.org.uk/reports/npca-state-of-the-nation-report-2025/](https://natcan.org.uk/reports/npca-state-of-the-nation-report-2025/)

<sup>iv</sup> Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening - 23-Year Follow-up. *N Engl J Med*. 2025 Oct 30;393(17):1669-1680. doi: [10.1056/NEJMoa2503223](https://doi.org/10.1056/NEJMoa2503223)

<sup>v</sup> Vickers A. Early Detection of Prostate Cancer - Time to Fish or Cut Bait. *N Engl J Med*. 2025 Oct 30;393(17):1742-1743. doi: [10.1056/NEJMe2509793](https://doi.org/10.1056/NEJMe2509793)

<sup>vi</sup> Norori N, Burns-Cox L, Blaney N et al. Using real world data to bridge the evidence gap left by prostate cancer screening trials, ESMO Real World Data and Digital Oncology, Volume 6, 2024, 100073, ISSN 2949-8201, doi: [10.1016/j.esmorw.2024.100073](https://doi.org/10.1016/j.esmorw.2024.100073)

<sup>vii</sup> Hugosson J, Månsson M, Wallström J et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. *N Engl J Med*. 2022 Dec 8;387(23):2126-2137. doi: [10.1056/NEJMoa2209454](https://doi.org/10.1056/NEJMoa2209454)

<sup>viii</sup> [thetimes.com/uk/healthcare/article/nhs-advisers-set-to-reject-routine-prostate-cancer-screening-ckznrp80p](https://www.thetimes.com/uk/healthcare/article/nhs-advisers-set-to-reject-routine-prostate-cancer-screening-ckznrp80p)

<sup>ix</sup> Prostate Cancer Research. [Prostate Cancer Screening: Impact on the NHS](https://www.prostatecancerresearch.org.uk/news/prostate-cancer-screening-impact-on-the-nhs); 2025

<sup>x</sup> Ng ABCD, Asif A, Agarwal R et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. *JAMA*. 2025 Oct 7;334(13):1170-1179. doi: [10.1001/jama.2025.13722](https://doi.org/10.1001/jama.2025.13722)

<sup>xi</sup> Prostate Cancer Research. [Socio-Economic Impact of Prostate Cancer Screening](https://www.prostatecancerresearch.org.uk/news/socio-economic-impact-of-prostate-cancer-screening); 2024

<sup>xii</sup> Prostate Cancer Research, *ibid*

<sup>xiii</sup> [healthwatch.co.uk/blog/2025-10-08/men-would-come-forward-prostate-cancer-screening](https://www.healthwatch.co.uk/blog/2025-10-08/men-would-come-forward-prostate-cancer-screening)

<sup>xiv</sup> Bratt O, Godtman RA, Jiborn T et al. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. *Eur Urol*. 2024 Mar;85(3):207-214. doi: [10.1016/j.eururo.2023.11.013](https://doi.org/10.1016/j.eururo.2023.11.013)

<sup>xv</sup> EU Council Recommendation 2022/2381 and Beating Cancer Plan updates (2024). [consilium.europa.eu/en/press/press-releases/2022/12/09/council-updates-its-recommendation-to-screen-for-cancer/](https://consilium.europa.eu/en/press/press-releases/2022/12/09/council-updates-its-recommendation-to-screen-for-cancer/)

<sup>xvi</sup> Prostate Cancer Foundation of Australia, Public Consultation: Draft 2025 Clinical Guidelines for the Early Detection of Prostate Cancer. [pcfa.org.au/public-consultation/](https://pcfa.org.au/public-consultation/)